X4 Pharmaceuticals Inc. is a Boston-based clinical-stage biopharmaceutical company dedicated to developing breakthrough therapies for rare and serious diseases, particularly those related to back disorders. Leveraging its proprietary technology, X4 is advancing a promising pipeline of investigational therapies designed to meet critical unmet medical needs and improve patient outcomes. With a strong commitment to innovative clinical development and a clear focus on underserved patient populations, X4 is strategically positioned to make a significant impact in the biopharmaceutical sector and potentially establish itself as a leader in therapeutic solutions. Show more

Location: 61 NORTH BEACON STREET, BOSTON, MA, UNITED STATES, 02134, Boston, MA, 02134, USA | Website: https://www.x4pharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

323.5M

52 Wk Range

$1.35 - $19.68

Previous Close

$3.70

Open

$3.66

Volume

385,605

Day Range

$3.66 - $4.00

Enterprise Value

277.8M

Cash

69.86M

Avg Qtr Burn

-27.82M

Insider Ownership

1.15%

Institutional Own.

41.75%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Mavorixafor (CXCR4 inhibitor) Details WHIM Syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavorixafor (CXCR4 inhibitor) Details Severe Congenital Neutropenia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavorixafor (CXCR4 inhibitor) Details Chronic Neutropenia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavorixafor (CXCR4 inhibitor) + ibrutinib Details Waldenstrom macroglobulinemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavorixafor (CXCR4 inhibitor) Details Renal cell carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.